Fetal Monitors in Massachusetts

Nexpring Health is a global MedTech company focused on Assisted Reproductive Technology (ART), formed in 2025 through the combination of Hamilton Thorne, Cook Medical's Reproductive Health business, FUJIFILM Irvine Scientific's Medical Media Business, and several other specialized fertility providers. Headquartered in Beverly, Massachusetts, the company brings together over 40 years of cumulative industry expertise to serve embryologists, clinicians, and fertility clinics worldwide. Nexpring Health offers a comprehensive end-to-end ART portfolio encompassing innovative devices, culture media, consumables, and support services designed for every stage of the IVF cycle—from pre-IVF diagnosis and sperm preparation through ovum pickup, fertilization, embryo development, embryo transfer, and cryopreservation. Key products include the Guardia™ Access Embryo Transfer Catheter family, Gynemed Specialty Media formulations, CASA systems for semen analysis, embryo culture media, cryopreservation equipment (Kryo series), incubators, aspiration needles, micromanipulation instruments, and laboratory monitoring systems. The company emphasizes streamlined workflows, product quality, and direct collaboration with ART professionals to address challenges in fertility clinic operations and improve patient outcomes.

Little Sparrows Technologies is an award-winning startup dedicated to advancing newborn care through innovative medical devices designed for resource-limited settings. The company's flagship product, the Bili-Hut™, is a portable, battery-operable neonatal phototherapy device for treating jaundice in newborns. The Bili-Hut features neonatologist-designed engineering, 180° wraparound light exposure, and enables treatment within 24 hours while supporting family-centered care and breastfeeding. The company also manufactures the Bili-Ruler™, a jaundice screening tool using digital image processing, and developmental care products including swaddling and positioning aids. All innovations focus on clinical effectiveness in low-resource environments. The Bili-Hut has received recognition from the Gates Foundation, USAID, and the National Institutes of Health, with recent randomized clinical pilot trial results validating its efficacy.